Moderna, Inc. $MRNA Shares Sold by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio decreased its position in Moderna, Inc. (NASDAQ:MRNA) by 17.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 110,125 shares of the company’s stock after selling 22,775 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in Moderna were worth $3,038,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. S Bank Fund Management Ltd acquired a new stake in Moderna in the first quarter valued at approximately $25,000. SVB Wealth LLC acquired a new stake in Moderna in the first quarter valued at approximately $28,000. CX Institutional grew its position in shares of Moderna by 1,129.8% during the second quarter. CX Institutional now owns 1,033 shares of the company’s stock worth $29,000 after buying an additional 949 shares in the last quarter. Costello Asset Management INC acquired a new stake in shares of Moderna during the first quarter worth approximately $30,000. Finally, Sentry Investment Management LLC acquired a new stake in shares of Moderna during the first quarter worth approximately $31,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Price Performance

Shares of MRNA opened at $27.60 on Thursday. The business’s fifty day moving average price is $26.52 and its 200 day moving average price is $27.49. Moderna, Inc. has a 12-month low of $23.15 and a 12-month high of $63.69. The stock has a market capitalization of $10.74 billion, a PE ratio of -3.67 and a beta of 2.01.

Moderna (NASDAQ:MRNA) last posted its earnings results on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.99) by $0.86. The company had revenue of $142.00 million for the quarter, compared to analysts’ expectations of $116.26 million. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The firm’s quarterly revenue was down 41.1% compared to the same quarter last year. During the same period last year, the business posted ($3.33) earnings per share. Moderna has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

MRNA has been the subject of a number of recent analyst reports. Cowen initiated coverage on shares of Moderna in a research report on Sunday, July 13th. They set a “hold” rating for the company. Leerink Partners decreased their price target on shares of Moderna from $18.00 to $15.00 and set an “underperform” rating for the company in a research report on Friday, August 22nd. JPMorgan Chase & Co. set a $26.00 price target on shares of Moderna in a research report on Friday, August 1st. Wells Fargo & Company reissued an “equal weight” rating on shares of Moderna in a research report on Sunday, July 13th. Finally, Barclays decreased their price target on shares of Moderna from $40.00 to $31.00 and set an “equal weight” rating for the company in a research report on Monday, August 4th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, fourteen have given a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $41.81.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.